Today, we are on the front line of the next great genomics revolution. By utilizing rapid advances in DNA sequencing, computing, and bioinformatics — together with our foundational intellectual property and proprietary DNA synthesis technologies — Synthetic Genomics is partnering with industry-leading companies to reprogram cells for the next-generation of medicines and bio-based products.
Our lead R&D programs focus on self-amplifying RNA for vaccines and therapeutics and novel cell factories for discovery and biomanufacturing. Many of our innovations already are taking shape through our partnerships with industry-leading companies.
DNA synthesis products and services, including the world’s first DNA printer, are offered through our subsidiary, SGI-DNA.